The need for the discovery and development of innovative technologies to improve the delivery of therapeutic and diagnostic agents in the body is widely recognized. The “next generation” therapies must be able to deliver drugs, therapeutic proteins and recombinant DNA to focal areas of disease or to tumors to maximize clinical benefit while limiting untoward side effects. The use of nanoscale technologies to design novel drug delivery systems and devices is a rapidly developing area of biomedical research that promises breakthrough advances in therapeutics and diagnostics.
Center for Drug Delivery and Nanomedicine (CDDN) serves to unify existing diverse technical and scientific expertise in biomedical and material science research at the University of Nebraska thereby creating a world class interdisciplinary drug delivery and nanomedicine program. This is realized by integrating established expertise in drug delivery, gene therapy, neuroscience, pathology, immunology, pharmacology, vaccine therapy, cancer biology, polymer science and nanotechnology at the University of Nebraska Medical Center (UNMC), the University of Nebraska at Lincoln (UNL) and Creighton University.
CDDN’s vision is to improve health by enhancing the efficacy and safety of new and existing therapeutic agents, diagnostic agents and genes through the discovery and application of innovative methods of drug delivery and nanotechnology. CDDN’s mission is to discover and apply knowledge to design, develop and evaluate novel approaches to improve the delivery of therapeutic agents, diagnostic agents and genes.
The COBRE Nebraska Center for Nanomedicine is supported by the National Institute of General Medical Science (NIGMS) grant 2P20 GM103480-07.